BioArctic
BIOA | ST
Overview
Corporate Details
- ISIN(s):
- SE0010323303 (+1 more)
- LEI:
- 549300Y0OI2WVUNHLC33
- Country:
- Sweden
- Address:
- Warfvinges väg 35, 112 51 Stockholm
- Website:
- https://www.bioarctic.se/en/
- Sector:
- Professional, scientific and technical activities
- Industry:
- Research and experimental development on natural sciences and engineering
Description
BioArctic is a Swedish research-intensive biopharmaceutical company focused on developing new, disease-modifying treatments and diagnostics for neurodegenerative disorders. The company's primary research areas include Alzheimer's disease, Parkinson's disease, and ALS. BioArctic's approach is to target the underlying causes of these diseases through innovative research and the development of antibodies and biomarkers. A key asset is its proprietary brain transporter technology designed to improve the delivery of antibody treatments across the blood-brain barrier. The company is known for its partnership with Eisai in developing lecanemab (Leqembi), a treatment for early Alzheimer's disease.
Stop Scraping. Start Analyzing.
You're viewing a fraction of the data available for BioArctic.
Get complete, real-time, and AI-ready data via the API the pros use.
Filings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-08-28 08:00 |
Interim Report
|
Swedish | 1.8 MB | |
| 2025-08-28 08:00 |
Interim Report
|
English | 1.6 MB | |
| 2025-08-26 07:05 |
M&A Activity
BioArctic och Novartis ingår options-, samarbets- och licensavtal som nyttjar B…
|
Swedish | 201.1 KB | |
| 2025-08-26 07:05 |
M&A Activity
BioArctic and Novartis sign an option, collaboration and license agreement usin…
|
English | 206.8 KB | |
| 2025-07-31 12:00 |
Regulatory News Service
Sales of Leqembi® totaled 23.1 billion yen in the second quarter 2025
|
English | 196.5 KB | |
| 2025-07-31 12:00 |
Earnings Release
Försäljningen av Leqembi® uppgick till 23,1 miljarder yen under det andra kvart…
|
Swedish | 223.3 KB | |
| 2025-06-13 08:00 |
Regulatory News Service
BioArctic to initiate next cohorts in exidavnemab Phase 2a study after positive…
|
English | 188.3 KB | |
| 2025-06-13 08:00 |
Regulatory News Service
BioArctic initierar nästa steg i fas 2a-studien av exidavnemab efter positiv sä…
|
Swedish | 223.8 KB | |
| 2025-05-30 18:30 |
Declaration of Voting Results & Voting Rights Announcements
Number of shares and votes in BioArctic AB (publ) as of May 30, 2025
|
English | 163.0 KB | |
| 2025-05-30 18:30 |
Declaration of Voting Results & Voting Rights Announcements
Antal aktier och röster i BioArctic AB (publ) per den 30 maj 2025
|
Swedish | 159.1 KB | |
| 2025-05-22 18:19 |
Post-Annual General Meeting Information
Kommuniké från årsstämma i BioArctic AB (publ)
|
Swedish | 194.1 KB | |
| 2025-05-22 18:19 |
Post-Annual General Meeting Information
Bulletin from the Annual General Meeting in BioArctic AB (publ)
|
English | 192.8 KB | |
| 2025-05-22 15:15 |
Legal Proceedings Report
BioArctic receives positive opinion for Orphan Medicinal Product Designation in…
|
English | 172.1 KB | |
| 2025-05-22 15:15 |
Regulatory News Service
BioArctic erhåller positiv rekommendation för särläkemedelsklassificering i EU …
|
Swedish | 190.7 KB | |
| 2025-05-21 08:00 |
Quarterly Report
|
Swedish | 14.5 MB |
Automate Your Workflow. Get a real-time feed of all BioArctic filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Need More History? Access decades of standardized financials for BioArctic via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2025-02-13 | Gunilla Osswald | Other | Sell | 40,000 | 8,821,200.00 SEK |
| 2025-02-13 | Gunilla Osswald | Other | Other | 40,000 | 3,344,000.00 SEK |
| 2025-02-13 | Sten Mikael Moge | Other | Sell | 6,000 | 1,323,180.00 SEK |
| 2025-02-13 | Sten Mikael Moge | Other | Other | 6,000 | 501,600.00 SEK |
| 2025-02-13 | Johanna Margareta Fälting | Other | Sell | 1,500 | 330,795.00 SEK |
| 2025-02-13 | Johanna Margareta Fälting | Other | Other | 2,500 | 209,000.00 SEK |
| 2025-02-13 | Johanna Margareta Fälting | Other | Other | 1,500 | 125,400.00 SEK |
| 2025-01-10 | Mikael Smedeby | Other | Buy | 730 | 148,920.00 SEK |
| 2024-12-19 | Oskar Bosson | Other | Sell | 2,000 | 446,000.00 SEK |
| 2024-12-19 | Oskar Bosson | Other | Sell | 871 | 195,626.60 SEK |
